Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that the UAE's Ministry of Health has granted marketing authorization for ORLADEYO (berotralstat), designed to prevent recurrent attacks in patients aged 12 and older suffering from hereditary angioedema. This approval marks a significant advancement in treatment options for these patients. BioCryst has partnered with NewBridge Pharmaceuticals for distribution across the Gulf Cooperation Council (GCC) and Iraq, aiming to enhance market access for this innovative therapy.
BioCryst Pharmaceuticals (BCRX) will present at the 2021 Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 p.m. ET. Additionally, they will showcase their presentation at the H.C. Wainwright 23rd Annual Global Investment Conference, available on-demand starting September 13, 2021, at 7:00 a.m. ET. Investors can access the live audio webcast and replays on BioCryst's website. The company focuses on developing oral medicines for rare diseases and has several products approved or in development, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options to 18 new employees. The options allow the purchase of 199,000 shares at an exercise price of $15.92 and $16.15, corresponding to the closing stock prices on August 31 and September 1, 2021, respectively.
The options will vest in four equal annual installments, starting one year after the grant date, and are part of the Inducement Equity Incentive Plan, valid for 10 years.
BioCryst Pharmaceuticals (BCRX) announced the U.S. Department of Health and Human Services (HHS) has ordered an additional 10,000 doses of its antiviral influenza therapy, RAPIVAB, for approximately $7 million. This purchase will bolster the Strategic National Stockpile as part of a $34.7 million contract from 2018 to supply up to 50,000 doses over five years. With this order, BioCryst will have delivered 40,000 doses, enhancing preparedness for the upcoming influenza season. RAPIVAB is approved for treating acute uncomplicated influenza in patients over six months old.
BioCryst Pharmaceuticals has appointed Steven Galson, M.D. to its board of directors. Galson, a former director of the FDA Center for Drug Evaluation and Research, brings extensive experience from his time at Amgen and various health agencies. His track record includes overseeing significant drug developments, which the company hopes will aid in commercializing its ORLADEYO® treatment and advancing pipeline candidates like BCX9930. This leadership change comes at a crucial time as BioCryst focuses on expanding treatment options for rare diseases.
BioCryst Pharmaceuticals (BCRX) has announced that Health Canada and Swissmedic have accepted the submission for ORLADEYO (berotralstat) for reviewing its potential to prevent recurrent attacks in patients with hereditary angioedema (HAE) aged 12 and older. This marks a significant milestone in the company's efforts to provide a targeted oral therapy for HAE patients, as no such therapies currently exist in these regions. CEO Jon Stonehouse emphasizes that approval could introduce an essential treatment option for patients and physicians in Canada and Switzerland.
BioCryst Pharmaceuticals (BCRX) has withdrawn its proposed public offering due to unfavorable market conditions. The company expressed confidence in its strong balance sheet, reporting $222.8 million in liquid assets as of June 30, 2021. With continued revenue growth from ORLADEYO®, BioCryst anticipates a cash runway extending into 2023 and the ability to leverage an additional $75 million from its credit facility. The firm remains focused on developing treatments for rare diseases while maintaining a strong financial position to support its ongoing projects.
BioCryst Pharmaceuticals (BCRX) announced a public offering to sell $200 million of its common stock and pre-funded warrants. The underwriters will have a 30-day option to purchase an additional 15% of the offering. Proceeds will support general corporate purposes, including development of ORLADEYO and BCX9930 for rare diseases, among other pipeline projects. The offering is contingent on market conditions and follows an effective shelf registration statement with the SEC.
BioCryst Pharmaceuticals reported $50.0 million in revenue for Q2 2021, up from $2.9 million a year earlier. The company's ORLADEYO (berotralstat) generated $28.5 million in net revenue, driven by a strong launch and increased patient access. Financial results included a $15 million milestone payment from a Japanese partner, while R&D expenses rose to $52.9 million. Despite growing revenues, the company reported a net loss of $43.2 million and does not provide detailed guidance for 2021. Cash and investments totaled $222.8 million.
BioCryst Pharmaceuticals (BCRX) announced the grant of inducement stock options for 12 new employees, totaling 222,500 shares. The options were issued on July 30, 2021, with an exercise price of $16.12, equal to the closing stock price on that date. Options will vest in equal annual installments over four years, contingent on the employees' continued service. This action follows Nasdaq Listing Rule 5635(c)(4), aimed at enhancing employee incentives and aligning their interests with shareholders.
